Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570749 · ClinicalTrials.gov registry record · Phase 2
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 784
- Enrollment target
NCT03570749 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 784 participants.
The verdict
NCT03570749, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 784 participants
- Enrollment target
Study Summary
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.
Interventions
- DRUG Placebo
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2025-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03570749
The ClinicalTrials.gov registry entry for NCT03570749 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 784 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03570749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03570749 about?
NCT03570749 is a clinical study titled "A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata". This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.
What is the current status of trial NCT03570749?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 784 participants. The study started on 2018-09-24. Estimated completion is 2025-01-29.
What interventions are being tested in trial NCT03570749?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03570749?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.